Trial Profile
A Multicentric Prospective Observational Registry to evaluate safety, efficacy and cost effectiveness of using Bivalirudin in an Acute Coronary Syndrome (ACS) patient population undergoing percutaneous coronary intervention (PCI) in India.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Bivalirudin (Primary)
- Indications Acute coronary syndromes; Thrombosis
- Focus Adverse reactions
- Sponsors The Medicines Company
- 15 Mar 2014 New trial record